Helene Rundqvist, PhD, Karolinska Institute, Stockholm, Sweden, shares findings from the PREFERABLE-EFFECT trial, which investigated the impact of a 9-month exercise intervention in patients with metastatic breast cancer. The intervention combined resistance and endurance exercises. Primary outcomes demonstrated significant reductions in fatigue and improved quality of life for patients who participated in the exercise regimen. Additionally, secondary outcomes, including pain and cost-effectiveness, were evaluated, along with exploratory outcomes involving inflammatory markers. Blood samples taken before the trial and at 3- and 6-month intervals revealed that the exercise intervention modulated cytokine levels and reduced systemic inflammation in the patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
